More than 3 million Americans have been diagnosed with emphysema, and millions more may have the condition without knowing it. According to the CDC, emphysema is a chronic, progressive lung disease that permanently destroys the tiny air sacs in the lungs, making it increasingly difficult to breathe. It falls under the broader umbrella of chronic obstructive pulmonary disease (COPD) and is overwhelmingly caused by cigarette smoking. While the damage already done cannot be undone, understanding emphysema opens the door to treatments that slow progression and improve quality of life. For an overview of chronic conditions, visit our medical conditions guide.
What Is Emphysema?
In healthy lungs, millions of tiny air sacs called alveoli cluster at the ends of the smallest airways like grapes on a vine. These thin-walled structures are where the essential work of breathing happens — oxygen passes from inhaled air into the bloodstream, and carbon dioxide passes from the blood into the air to be exhaled. Emphysema destroys the walls between these alveoli, merging small, efficient air sacs into larger, less effective ones.
This destruction has two critical consequences. First, the surface area available for gas exchange shrinks dramatically. Second, the loss of the alveolar walls eliminates the structural support that normally holds the small airways open. Without this support, the airways collapse during exhalation, trapping stale, carbon dioxide-rich air in the lungs. This air trapping is what gives emphysema patients their characteristic barrel-shaped chest and their struggle to exhale completely.
The NHLBI classifies emphysema as one of the two main conditions under the COPD umbrella, alongside chronic bronchitis. In practice, most people with COPD have elements of both, though one may predominate. Emphysema tends to dominate in patients with more significant shortness of breath and air trapping, while chronic bronchitis features more prominently in those with persistent cough and mucus production.
Causes
Cigarette smoking is the cause of emphysema in approximately 85-90% of cases. Tobacco smoke contains thousands of chemicals that trigger a destructive inflammatory response in the lungs. Immune cells called neutrophils and macrophages are recruited to the airways and release enzymes (particularly elastase) that break down elastin — the protein responsible for the alveoli’s elastic recoil. Over decades, this continuous enzymatic assault progressively destroys alveolar walls.
Alpha-1 antitrypsin (AAT) deficiency is the primary non-smoking cause of emphysema. Alpha-1 antitrypsin is a protein produced by the liver that normally protects the lungs from elastase damage. People with AAT deficiency lack adequate levels of this protective protein, leaving their lungs vulnerable to damage from even normal inflammatory processes. AAT deficiency affects roughly 1 in 2,000-5,000 people of European descent and can cause emphysema in people as young as their 30s or 40s, especially if they also smoke.
Other contributing factors include long-term exposure to secondhand smoke, occupational dust and chemicals (coal dust, grain dust, chemical fumes), indoor and outdoor air pollution, and a history of recurrent respiratory infections in childhood. According to the Mayo Clinic, marijuana smoke may also contribute to emphysema, though research is still limited. Aging itself causes some loss of alveolar structure, but this is a minor contributor compared to smoking.
Symptoms
Emphysema develops insidiously over years, and early symptoms are easy to dismiss. The primary symptom is progressive shortness of breath — initially noticeable only during vigorous exercise, then during moderate activity like climbing stairs, and eventually during simple daily tasks like dressing or bathing. This gradual onset means many people unconsciously adapt by reducing their activity levels, mistaking the decline for normal aging.
Other common symptoms include a chronic, often non-productive cough (or one that produces only small amounts of clear sputum), wheezing, chest tightness, and a sensation of not being able to get a full breath. As the disease advances, patients may develop a barrel-shaped chest (from chronic air trapping), use of accessory muscles for breathing (neck and shoulder muscles working visibly with each breath), pursed-lip breathing (an instinctive technique that helps keep airways open during exhalation), and unintentional weight loss.
In advanced emphysema, reduced oxygen levels can cause a bluish tint to the lips and fingernails (cyanosis), and chronic low oxygen can lead to secondary complications including pulmonary hypertension (high blood pressure in the lung arteries) and right-sided heart failure (cor pulmonale). The Cleveland Clinic notes that people with emphysema are sometimes described as “pink puffers” because of their labored breathing and relatively maintained oxygen levels in earlier stages, in contrast to the “blue bloaters” of chronic bronchitis.
Diagnosis
Spirometry is the essential diagnostic test for emphysema and COPD. It measures how much air you can forcefully exhale in one second (FEV1) and the total amount you can exhale (FVC). A reduced FEV1/FVC ratio (below 0.70) that doesn’t fully improve with a bronchodilator indicates fixed airflow obstruction consistent with emphysema/COPD. The severity of airflow limitation is graded by the GOLD classification system based on FEV1 percentage of predicted.
CT scanning of the chest can directly visualize the destruction of alveolar walls, showing areas of low attenuation (dark areas where lung tissue has been destroyed). High-resolution CT is particularly useful for characterizing the distribution and severity of emphysema and for surgical planning. Chest X-ray may show hyperinflated lungs and a flattened diaphragm but is less sensitive than CT for detecting early emphysema.
Pulmonary function tests (PFTs) beyond basic spirometry — including lung volumes and diffusing capacity (DLCO) — help characterize the physiological impact of emphysema. Increased total lung capacity and residual volume reflect air trapping, while a reduced DLCO reflects loss of gas-exchanging surface area. Alpha-1 antitrypsin testing should be performed at least once in every person diagnosed with emphysema or COPD. Arterial blood gas analysis and pulse oximetry assess oxygenation. According to the NHLBI, early diagnosis through spirometry screening in at-risk individuals allows earlier intervention and better outcomes.
Treatment: Smoking Cessation
Quitting smoking is the single most important treatment for emphysema — the only intervention proven to slow the accelerated decline in lung function. While quitting can’t reverse existing damage, it returns the rate of lung function decline to near-normal (the age-related rate experienced by non-smokers). The CDC emphasizes that it’s never too late to quit — benefits occur at any age and any stage of disease.
Effective cessation aids include nicotine replacement therapy (patches, gum, lozenges, inhaler, nasal spray), varenicline (Chantix), and bupropion (Wellbutrin/Zyban). Combining medication with behavioral support (counseling, quit-lines, support groups) produces the highest success rates. Most smokers require multiple quit attempts — each one provides valuable experience and brings you closer to permanent cessation.
Treatment: Medications
Bronchodilators are the mainstay of pharmacological treatment. Long-acting muscarinic antagonists (LAMAs) like tiotropium and long-acting beta-agonists (LABAs) like salmeterol and formoterol are used as daily maintenance therapy. They relax airway muscles, reduce air trapping, and improve exercise capacity. Short-acting bronchodilators (albuterol, ipratropium) provide quick relief for acute symptoms.
Inhaled corticosteroids (ICS) are added for patients with frequent exacerbations, particularly those with features of asthma-COPD overlap or elevated blood eosinophil counts. Triple therapy inhalers combining a LAMA, LABA, and ICS in a single device have shown benefits for reducing exacerbations in appropriate patients. The Mayo Clinic notes that inhaler technique is critical — if you’re not using your inhaler correctly, you’re not getting the full benefit of the medication. Ask your healthcare provider to observe your technique.
Roflumilast, an oral phosphodiesterase-4 inhibitor, may be added for patients with severe emphysema/COPD and frequent exacerbations despite inhaler therapy. Long-term azithromycin has shown benefit in reducing exacerbation frequency in selected patients. Oral corticosteroids are reserved for acute exacerbations and should be used for the shortest duration possible due to significant side effects with chronic use.
Treatment: Non-Pharmacological Approaches
Pulmonary Rehabilitation
Pulmonary rehabilitation is one of the most effective interventions for emphysema, consistently producing improvements in exercise capacity, breathlessness, and quality of life that often exceed what medications achieve. Programs typically run six to twelve weeks and include supervised exercise training, education, breathing techniques (pursed-lip breathing, diaphragmatic breathing), nutritional counseling, and psychosocial support. According to research published in the Cochrane Database of Systematic Reviews, pulmonary rehabilitation is recommended for all patients with emphysema who remain symptomatic despite optimal medical therapy.
Oxygen Therapy
Long-term supplemental oxygen — used at least 15-18 hours per day — improves survival in patients with severe emphysema and chronic low blood oxygen levels (resting PaO2 below 55 mmHg or SpO2 below 88%). It also reduces pulmonary hypertension, improves exercise tolerance, and enhances cognitive function. Modern portable oxygen concentrators are smaller and lighter than ever, allowing patients to maintain mobility. Understanding healthcare costs is relevant when managing the ongoing expenses of oxygen equipment and supplies.
Surgical and Bronchoscopic Options
Lung volume reduction surgery (LVRS) removes the most severely damaged portions of the lungs, allowing healthier tissue to expand and the diaphragm to work more effectively. The NETT trial demonstrated that LVRS improves exercise capacity and survival in selected patients with upper-lobe-predominant emphysema and low baseline exercise capacity.
Bronchoscopic lung volume reduction using endobronchial valves is a less invasive alternative for patients with severe emphysema, intact fissures between lung lobes, and significant hyperinflation. The one-way valves prevent air from entering the most damaged lobe, allowing it to deflate and giving healthier lung tissue room to function. Lung transplantation remains an option for carefully selected patients with end-stage emphysema who meet eligibility criteria.
Preventing Exacerbations
Acute exacerbations — episodes of worsening symptoms beyond normal day-to-day variation — accelerate lung function decline, reduce quality of life, and increase mortality risk. Prevention strategies are critical: take maintenance medications consistently, get annual influenza and pneumonia vaccinations (and stay current on COVID-19 vaccination), practice good hand hygiene, avoid crowds during respiratory illness season, and monitor air quality.
Know the early warning signs of an exacerbation: increased shortness of breath, more coughing, change in sputum color or volume, increased sputum thickness, fever, or worsening fatigue. Having a written action plan that specifies when to increase bronchodilator use, when to start oral steroids or antibiotics, and when to seek emergency care helps you respond quickly and may prevent hospitalization.
Frequently Asked Questions
Can emphysema be reversed?
No. The alveolar destruction that defines emphysema is permanent — the body cannot regrow these structures. However, quitting smoking stops further accelerated decline, medications can optimize remaining lung function, and pulmonary rehabilitation can dramatically improve your ability to use what lung capacity you have. Many people experience meaningful improvement in symptoms and quality of life even though the underlying damage persists.
How long can you live with emphysema?
Life expectancy depends on severity at diagnosis, whether you continue smoking, how well you respond to treatment, and your overall health. Many people with mild-to-moderate emphysema live for decades after diagnosis, particularly if they quit smoking. The BODE index (body mass index, airflow obstruction, dyspnea severity, exercise capacity) is a validated tool for estimating prognosis in COPD/emphysema.
Is emphysema the same as COPD?
Emphysema is one of the two main conditions under the COPD umbrella (the other being chronic bronchitis). Most people with COPD have features of both. COPD is the broader diagnostic term used in clinical practice; emphysema specifically refers to the destruction of alveolar walls and air trapping. When your doctor says “COPD,” they may mean emphysema, chronic bronchitis, or both.
Can non-smokers get emphysema?
Yes, though it’s less common. Alpha-1 antitrypsin deficiency is the most well-known cause of emphysema in non-smokers. Long-term exposure to secondhand smoke, occupational dusts and chemicals, indoor and outdoor air pollution, and a history of severe childhood respiratory infections can also contribute. If you develop emphysema without a significant smoking history, AAT deficiency testing is essential.
Does emphysema qualify for disability?
Severe emphysema can qualify for Social Security disability benefits if your pulmonary function tests meet specific criteria (generally an FEV1 at or below certain thresholds based on height) or if you can demonstrate that your condition prevents you from performing any substantial gainful activity. Documentation from your pulmonologist, including spirometry, arterial blood gas results, and exercise testing, supports disability applications.
Breathing Better With Emphysema
Emphysema changes the way you breathe, but it doesn’t have to define the way you live. Quit smoking if you haven’t already — this is non-negotiable. Engage fully in pulmonary rehabilitation — the evidence is unequivocal that it helps. Take your medications as prescribed, learn and practice breathing techniques, stay as physically active as your lungs allow, and maintain good nutrition (being underweight is a significant risk factor for poor outcomes in emphysema).
Plan ahead for exacerbations — keep an action plan visible, know when to escalate care, and don’t wait too long to seek help. Stay current on vaccinations. And while the damage to your lungs cannot be reversed, every positive step you take preserves what you have and maximizes what it can do. Living well with emphysema means working with your body’s remaining capacity, not giving up on it.